

Takeshi Nagasaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4424240/publications.pdf>

Version: 2024-02-01

41
papers

2,323
citations

361045

20
h-index

344852

36
g-index

47
all docs

47
docs citations

47
times ranked

4003
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 849-859.	3.0	425
2	Fecal MicroRNAs as Novel Biomarkers for Colon Cancer Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1766-1774.	1.1	310
3	The CpG Island Methylator Phenotype and Chromosomal Instability Are Inversely Correlated in Sporadic Colorectal Cancer. <i>Gastroenterology</i> , 2007, 132, 127-138.	0.6	264
4	Colorectal Cancer With Mutation in BRAF, KRAS, and Wild-Type With Respect to Both Oncogenes Showing Different Patterns of DNA Methylation. <i>Journal of Clinical Oncology</i> , 2004, 22, 4584-4594.	0.8	202
5	Somatic Hypermethylation of <i>MSH2</i> Is a Frequent Event in Lynch Syndrome Colorectal Cancers. <i>Cancer Research</i> , 2010, 70, 3098-3108.	0.4	167
6	An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers. <i>PLoS ONE</i> , 2010, 5, e9393.	1.1	136
7	Analysis of Fecal DNA Methylation to Detect Gastrointestinal Neoplasia. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1244-1258.	3.0	122
8	Mutations in Both KRAS and BRAF May Contribute to the Methylator Phenotype in Colon Cancer. <i>Gastroenterology</i> , 2008, 134, 1950-1960.e1.	0.6	114
9	AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	91
10	Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. <i>International Journal of Cancer</i> , 2008, 122, 2429-2436.	2.3	62
11	Poor prognosis of <i>KRAS</i> or <i>BRAF</i> mutant colorectal liver metastasis without microsatellite instability. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2013, 20, 223-233.	1.4	50
12	Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer. <i>Cancer Letters</i> , 2019, 444, 127-135.	3.2	40
13	Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). <i>British Journal of Cancer</i> , 2019, 121, 222-229.	2.9	37
14	PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. <i>Scientific Reports</i> , 2019, 9, 4633.	1.6	37
15	Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. <i>PLoS ONE</i> , 2018, 13, e0195655.	1.1	30
16	Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 17796-17803.	1.4	28
17	Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics. <i>Gut</i> , 2015, 64, 627-635.	6.1	27
18	The rare BRAF V600E mutation as a possible indicator of poor prognosis in rectal carcinoma – a report of a case. <i>BMC Medical Genetics</i> , 2015, 16, 1.	2.1	24

#	ARTICLE	IF	CITATIONS
19	Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles. <i>Oncotarget</i> , 2018, 9, 16477-16488.	0.8	23
20	Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy. <i>International Journal of Cancer</i> , 2019, 144, 2169-2180.	2.3	22
21	Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors. <i>Journal of Translational Medicine</i> , 2018, 16, 5.	1.8	21
22	Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. <i>Acta Medica Okayama</i> , 2011, 65, 169-77.	0.1	18
23	Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency. <i>Liver Cancer</i> , 2019, 8, 239-254.	4.2	14
24	Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study). <i>International Journal of Clinical Oncology</i> , 2019, 24, 1223-1230.	1.0	9
25	Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations. <i>Clinical Epigenetics</i> , 2021, 13, 117.	1.8	8
26	Comparison of outcomes between symptomatic and asymptomatic patients with colorectal cancer: a propensity score-matched analysis of surgical invasiveness, medical costs and oncological outcomes. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000146.	1.1	7
27	Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C ³) study. <i>BMJ Open</i> , 2016, 6, e011454.	0.8	6
28	BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage I-IV colorectal cancer. <i>Oncology Letters</i> , 2017, 15, 2195-2201.	0.8	6
29	Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer. <i>Oncology Letters</i> , 2020, 19, 2685-2694.	0.8	6
30	Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1557-1569.	1.2	5
31	Detection of fecal DNA methylation for colorectal neoplasia: does it lead to an optimal screening test?. <i>Acta Medica Okayama</i> , 2006, 60, 249-56.	0.1	5
32	A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study. <i>Oncology Letters</i> , 2018, 17, 1980-1985.	0.8	3
33	Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. <i>Okayama Igakkai Zasshi</i> , 2010, 122, 107-112.	0.0	1
34	Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC) <i>Tj ETQq0 0 0 rgBTi/Overlock 10 Tf 50 1</i>		
35	Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer. <i>Future Science OA</i> , 2021, 7, FSO757.	0.9	1
36	Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Prognostic Nutritional Index as a Predictor of Postoperative Outcome in Patients Aged 85 Years or Older After Colorectal Cancer Surgery. <i>Indian Journal of Surgery</i> , 2020, 82, 874-878.	0.2	0
38	Natural history of epithelioid hemangioendothelioma that progressed over 20 years. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28261.	0.8	0
39	Adenocarcinoma in the jejunum 20 years after surgery for familial adenomatous polyposis. <i>Okayama Igakkai Zasshi</i> , 2017, 129, 111-114.	0.0	0
40	Analysis of UGT1A1 polymorphisms and RAS: RAF mutations based on phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 565-565.	0.8	0
41	Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study. <i>European Journal of Cancer</i> , 2022, 169, 166-178.	1.3	0